Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk


 

FROM THE AACR ANNUAL MEETING

Pelvic inflammatory disease caused by chlamydia appears to significantly increase the risk of ovarian cancer, according to research to be presented at the annual meeting of the American Association for Cancer Research.

The finding, replicated in two large databases, suggests that promptly treating the infection might reduce the lifetime risk of developing ovarian cancer, Britton Trabert, PhD, said during a press briefing held in advance of the meeting.

Dr. Britton Trabert, National Cancer Institute, Bethesda, Md.

Dr. Britton Trabert

“Although these findings need to be replicated, they suggest potential ovarian cancer risk reduction through targeted treatment of chlamydia infections,” said Dr. Trabert, the Earl Stadtman Investigator at the National Cancer Institute.

The study portends both promise and challenge, according to Elaine R. Mardis, PhD, who comoderated the session.

Pages

Recommended Reading

New 9-valent HPV vaccine is efficacious, well tolerated
MDedge Dermatology
Contamination prompts voluntary injectables recall
MDedge Dermatology
ASCO: Precision medicine initiatives take wing
MDedge Dermatology
Single HPV vaccine dose appears as effective as full course
MDedge Dermatology
9-valent HPV vaccine equally effective in adolescents, young women
MDedge Dermatology
New cancer cases to reach nearly 2.4 million in 2035 – AACR
MDedge Dermatology
Cancer prevention field riding high into the new year
MDedge Dermatology
Bone marrow transplant cures severe HPV disease in GATA2 immunodeficiency
MDedge Dermatology
Incidence of HPV-associated cancers on the rise
MDedge Dermatology
Telling her she has cancer: A patient-centered approach to breaking bad news
MDedge Dermatology